baxdrostat
Phase 2- Indications
- Treatment-resistant hypertension, Primary aldosteronism, Chronic kidney disease, Uncontrolled hypertension
Company intelligence / Profile preview
CinCor Pharma
Waltham, Massachusetts, United Statesastrazeneca.com ↗
- Ownership
- Private
- Employees
- ~19
- Development stage
- Phase 2
01
Overview
Baxdrostat demonstrated statistically significant reductions in systolic blood pressure in treatment-resistant hypertension patients during Phase II trials. The BrigHtn trial met its primary endpoint with an average placebo-adjusted reduction of ~11 mmHg at the highest dose. Safety and tolerability were favorable. The HALO trial further confirmed efficacy and safety, supporting advancement to pivotal Phase III studies.
- Therapeutic areas
- EndocrinologyCardiovascularNephrology
- Modalities
- Small molecules (notably oral small molecule inhibitors)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Exclusive worldwide license for baxdrostat remained post-acquisition by AstraZeneca
Beyond the preview
Go deeper on CinCor Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CinCor Pharma.